Bright Minds Biosciences Inc. (DRUG) NASDAQ
76.78
-4.24(-5.23%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
76.78
-4.24(-5.23%)
Currency In USD
Address
1500 – 1055 West Georgia Street
New York City, BC V6E 4N7
Canada
Phone
647 407 2515
Website
Sector
Healthcare
Industry
Biotechnology
Employees
26
First IPO Date
March 22, 2021
| Name | Title | Pay | Year Born |
| Ian McDonald | Co-Founder, Chief Executive Officer, President & Director | 0 | 1988 |
| Ryan E. S. K. Cheung | CFO & Corporate Secretary | 97,182 | 1978 |
| Stephen D. Collins | Chief Medical Officer | 227,375 | 1953 |
| Jan Torleif Pedersen | Chief Science Officer & Director | 528,997 | 1965 |
| Emer Leahy | Consultant | 0 | 1967 |
| Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer | 0 | 1989 |
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.